// App-Quantinova.ai

124 : Periop-01: A randomized controlled trial of extended perioperative tinzaparin to improve disease-free survival in patients with resectable colorectal cancer.

Researchers

Presenter

  • Rebecca Ann C Auer

Principal Investigators

  • Michael Ott

  • Muriel Brackstone

  • Shady Ashamalla

  • Timothy R. Asmis

  • Marylise Boutros

  • Antonio Caycedo Marulanda

  • Shiva Jayaraman

  • Derek J. Jonker

  • Husein Moloo

  • Sunil Patel

  • Silvana Spadafora

  • Steven MacLellan

  • Ranjeeta Mallick

  • Peter Stotland

  • Vicky Tagalakis

  • Daniel C. Trottier

  • Joel Weaver

  • Marc Carrier

Medical Centers

  • Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON, Canada

  • Sunnybrook Health Sciences Centre, Odette Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Schulich School of Medicine, London Health Sciences Centre, University of Western Ontario, London, ON, Canada

  • Schulich School of Medicine, London Health Sciences Centre, University of Western Ontario, London, ON, Canada

  • Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON, Canada

  • Jewish General Hospital/ McGill Univeristy, Montreal, QC, Canada

  • Kingston Health Science Center & Queen’s University, Kingston (ON), Canada

  • St. Joseph's Health Center, University of Toronto, Toronto, ON, Canada

  • Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON, Canada

  • The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada

  • Group Health Centre and Algoma Regional Cancer Program, Sault Ste. Marie, ON, Canada

  • Sunnybrook Hospital, University of Toronto, Toronto, ON, Canada

  • The Ottawa Hospital Research Institute, Ottawa, ON, Canada

  • Toronto General Hospital, University of Toronto, Toronto, ON, Canada

  • Montfort Hospital, Ottawa, ON, Canada

  • Queensway Carleton Hospital, Ottawa, ON, Canada

  • Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Oncology (ONC)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

  • Colorectal Cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Tinzaparin

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Controlled

Phase

  • N/A

Study Id's

  • NCT01455831

Sponsors

  • Canadian Institute of Health Research and Leo Pharma Clinical trial

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved